FDA Denies Approval of Onpattro for Cardiomyopathy of ATTR Amyloidosis
source: shutterstock.com

FDA Denies Approval of Onpattro for Cardiomyopathy of ATTR Amyloidosis

  In 2018, the U.S. Food and Drug Administration (FDA) approved Onpattro (patisiran) as a treatment for polyneuropathy in people with hereditary transthyretin-mediated (ATTR) amyloidosis. Onpattro is an intravenously administered,…

Continue Reading FDA Denies Approval of Onpattro for Cardiomyopathy of ATTR Amyloidosis
RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy
source: pixabay.com

RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

  Gene therapy has the potential to improve outcomes among individuals across various disease spectrums. In the case of clinical-stage biotechnology company Rocket Pharmaceuticals, the company is working to develop…

Continue Reading RP-A601 Granted Orphan Drug and Fast Track Designations for Rare Cardiomyopathy

New Machine-Learning Model Shows Individuals If They’re at Risk of Rare Cardiomyopathy

According to a recent article, investigators created a machine learning model in order to identify if patients are at risk of rare cardiomyopathy. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Transthyretin amyloid cardiomyopathy…

Continue Reading New Machine-Learning Model Shows Individuals If They’re at Risk of Rare Cardiomyopathy

First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA

Transthyretin-Mediated Amyloidosis Cardiomyopathy The FDA has just approved the very first treatment for hereditary or wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).  ATTR-CM is a rare disease that occurs when amyloids, an…

Continue Reading First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA